Literature DB >> 15001556

Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells.

Gianluca Aguiari1, Manuela Banzi, Stefania Gessi, Yiqiang Cai, Emanuela Zeggio, Elisa Manzati, Roberta Piva, Elisabetta Lambertini, Luisa Ferrari, Dorien J Peters, Francesco Lanza, Peter C Harris, Pier Andrea Borea, Stefan Somlo, Laura Del Senno.   

Abstract

Polycystin-2 (PC2), encoded by the PKD2 gene, mutated in 10-15% of autosomal-dominant polycystic kidney disease (ADPKD) patients, is a Ca2+-permeable cation channel present in kidney epithelia and other tissues. As PC2 was found expressed in B-lymphoblastoid cells (LCLs) and Ca2+ signaling pathways are important regulators of B cell function activities, we investigated whether PC2 plays some role in B-LCLs. In LCLs, PC2 was found mainly in ER membranes but ~8 times less than in kidney HEK293 cells. The same reductions were found in PKD2 and PKD1 RNA; thus, PKD genes maintained, in LCLs, the same reciprocal proportion as they do in kidney cells. In LCLs obtained from subjects carrying PKD2 mutations (PKD2-LCLs) and showing reduced PC2 levels, intracellular Ca2+ concentrations evoked by platelet-activating factor (PAF), were significantly lower than in non-PKD-LCLs. This reduction was also found in PKD1-LCLs but without PC2 reductions. Likewise, cell proliferation, which is controlled by Ca2+, was reduced in PKD2- and PKD1-LCLs. Moreover, in LCLs with PKD2 nonsense mutations, aminoglycoside antibiotics reduced the PC2 defect by promoting readthrough of stop codons. Therefore, PC2 and PC1 are functionally expressed in LCLs, which provide a model, easily obtainable from ADPKD patients, to study PKD gene expression and function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001556     DOI: 10.1096/fj.03-0687fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

Review 1.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 3.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

4.  Polycystin-2 cation channel function in the human syncytiotrophoblast is regulated by microtubular structures.

Authors:  Nicolás Montalbetti; Qiang Li; Yuliang Wu; Xing-Zhen Chen; Horacio F Cantiello
Journal:  J Physiol       Date:  2007-01-04       Impact factor: 5.182

Review 5.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  ADPKD: molecular characterization and quest for treatment.

Authors:  Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

7.  Overexpression of Trpp5 contributes to cell proliferation and apoptosis probably through involving calcium homeostasis.

Authors:  Yan Xiao; Xiaoyan Lv; Ge Cao; Guohui Bian; Jingjing Duan; Jianzhong Ai; Huan Sun; Qingwei Li; Qiutan Yang; Tielin Chen; Danhua Zhao; Ruizhi Tan; Yuhang Liu; Yidong Wang; Zheng Zhang; Yang Yang; Yuquan Wei; Qin Zhou
Journal:  Mol Cell Biochem       Date:  2009-12-31       Impact factor: 3.396

8.  Polycystin-1, 2, and STIM1 interact with IP(3)R to modulate ER Ca release through the PI3K/Akt pathway.

Authors:  Netty G Santoso; Liudmila Cebotaru; William B Guggino
Journal:  Cell Physiol Biochem       Date:  2011-06-17

Review 9.  Making sense of nonsense GABA(A) receptor mutations associated with genetic epilepsies.

Authors:  Jing-Qiong Kang; Robert L Macdonald
Journal:  Trends Mol Med       Date:  2009-08-31       Impact factor: 11.951

10.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; Timea Kovaçs; Eric Sorscher; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.